[O2–09–02]: EVALUATION OF SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MEDI1814, A BETA‐AMYLOID 42 (Aβ42)‐SPECIFIC ANTIBODY, IN PATIENTS WITH MILD‐MODERATE ALZHEIMER'S DISEASE. (1st July 2017) - Ostenfeld, Thor; Pomfret, Michael; Billinton, Andy; Chessell, Iain; Chessell, Tharani; Lindqvist, Eva; Valencia, Zulma Santisteban; Groves, Maria; Narwal, Rajesh; Tatipalli, Manasa; Lee, Nancy; Turner, Richard; et al.